Neurocrine Biosciences Community

Catalysts Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u $22,999.80 Ingrezza@ Ingrezza (valbenazine) costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength. INGREZZA Capsule 40 MG $310.80 INGREZZA SPRINKLE Capsule 40 MG $310.80 Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Key Takeaways Delayed CRENESSITY launch and INGREZZA challenges could suppress short-term revenue growth expectations and net margins. Expanding INGREZZA sales and increased R&D investment raise immediate costs before future revenue gains materialize.

Key Takeaways CRENESSITY and INGREZZA provide strong long-term growth potential through expanded market reach, diversified revenues, and favorable healthcare trends supporting premium pricing. An advancing clinical pipeline and industry-tailwinds in neuroscience R&D position the company for accelerated innovation, pipeline progression, and reduced single-product dependency.

Key Takeaways Neurocrine's growth is driven by the successful INGREZZA and CRENESSIA launches, with anticipated future success from its robust R&D pipeline. Strategic investments in sales force expansion and R&D bolster revenue growth and improve net margins, ensuring long-term profitability.